Barif 40
- Barif tablets effectively manage chronic hyperuricemia associated with gout by inhibiting serum uric acid production through targeted xanthine oxidase inhibition.
- Tailored dosage regimen ensures personalized treatment, starting with an initial daily intake and subsequent adjustments based on individual response.
- Proactive measures are recommended for gout flare prevention, enhancing patient safety and adherence to treatment.
- Barif tablets have minimal impact on renal and hepatic function, promoting overall patient well-being.
- Contraindications are carefully considered to prioritize patient safety, ensuring optimal management of gout symptoms.